• Press Release

Jameel Health & LPIXEL Announce Strategic Collaboration to Enhance Medical Image Diagnosis Using AI Technology in MENAT and Global South Regions

Tokyo, JAPAN, – LPIXEL Inc., through Abdul Latif Jameel General Trading Co., Japan, is excited to announce a strategic collaboration with Jameel Health to distribute LPIXEL’s next-generation AI medical imaging diagnostic support technology, EIRL, across selected MENAT and Global South markets.
The EIRL series by LPIXEL heralds a new era in AI-driven medical diagnostics, offering an accurate, efficient, and streamlined solution to support clinicians in interpreting medical images amidst the increasing demand for diagnostic imaging. The lineup, consisting of six products covering radiology (X-ray, CT, and MRI) and real-time colonoscopy, supports diagnostics across multiple medical specialties, including neurology, pulmonology, and gastroenterology. Products like EIRL Chest Screening5 and EIRL Brain Aneurysm help prevent the oversight of lung nodules and cerebral aneurysms, potentially improving clinical outcomes for patients.
Since its establishment in 2014, LPIXEL has emerged as a pioneer in AI image analysis. EIRL products have earned the trust of clinicians across Japan, performing over 6.4 million analyses in more than 800 medical institutions1.
This strategic collaboration aims to provide clinicians in the MENAT region with powerful diagnostic tools to enhance the quality of medical care and improve patient outcomes through the early detection of diseases using AI technology.

1 Cumulatively, as of May 2024. Trials included.
2 EIRL Aneurysm – Approval no: 30100BZX00142000
3 EIRL Brain Metry – Certification no: 230AGBZX00107Z00
4 EIRL Brain Segmentation – Certification no: 303AGBZX00043Z00
5 Chest Screening is a package containing the following products:
EIRL Chest XR – Approval number: 30400BZX00285000, EIRL Chest Metry – Certification number: 302AGBZX00101000
6 EIRL Chest CT – Certification no: 304AGBZX00037Z00
7 EIRL Colon Polyp – Approval number: 30400BZX00259000

Jameel Health, through Abdul Latif Jameel General Trading Co., Japan, aims to widely promote LPIXEL’s technology as a medical diagnostic support tool through unique alliances with universities and hospitals across the Middle East. Initially, the exclusive distribution will focus on KSA and UAE, with plans for extended distribution in selected MENAT and Global South regions.

About Jameel Health
Backed by Abdul Latif Jameel, one of the most respected diversified family businesses and investors with a 75-year heritage, deep roots, and established networks alongside a multi-sector presence in 30 countries across six continents, Abdul Latif Jameel Health is uniquely positioned as a trusted partner in realizing major innovations and opportunities in the healthcare world.
Jameel Health reflects the Jameel family’s long-established commitment to innovating for a better future through Community Jameel, an international organization supporting science and technology-led solutions to global challenges. Community Jameel and MIT co-founded the Abdul Latif Jameel Clinic for Machine Learning in Health (Jameel Clinic) in September 2018 – which has rapidly become the very epicenter of AI and healthcare at MIT – and the Abdul Latif Jameel Institute for Disease and Emergency Analytics (Jameel Institute) co-founded with Imperial College London, in October 2019, using novel data analytics to reduce global risk of preventable disease most recently including the 2020 COVID-19 pandemic, and strengthening health systems in the most fragile settings.
Jameel Health takes this commitment into the commercial environment addressing tangible real-world needs today, for a better tomorrow. It is focused on health care inclusion in the global south, accelerating access to modern medical care for those who need it most by opening up/growing new markets for distribution of existing solutions and investing in the future of MedTech.
Abdul Latif Jameel actively invests in innovative, early-stage and breakthrough ventures and technology, aiming to positively shape the future of core industries driving the global economy through its’ investments that span medical and healthcare industries, from pharmaceuticals and vaccines to cutting-edge medical technology, along with emergent technologies across FinTech, InsurTech, electric vehicles and future mobility solutions.
For further information, visit:

About Abdul Latif Jameel
Abdul Latif Jameel is a global investor and diversified, private family-owned business celebrating its 75th anniversary in 2020. It is comprised of a number of independent entities across a number of major industry sectors including: passenger vehicles; commercial vehicles and equipment; logistics; engineering and manufacturing; financial services; energy and environmental services, health; land and real estate: consumer products and advertising and media. Strong trusted networks and long-established relationships make Abdul Latif Jameel a powerful business and investment collaborator across the world. It currently has a presence in more than 30 countries on six continents and employs more than 11,000 people of over 40 nationalities. For further information, visit:
For press inquiries, contact, or call +971 4 448 0906 (GMT +4 hours UAE)

About LPIXEL Inc
(LPIXEL Inc. headquartered in Otemachi, Chiyoda-ku, Tokyo, Japan)
Established in 2014, LPIXEL is a leading provider of artificial intelligence-based image analysis technologies within the medical and life science industries.
Dedicated to improving the lives of clinicians and the health of patients, LPIXEL’s flagship series of Software as a Medical Device (SaMD) products, ‘EIRL’, assists clinicians with the interpretation of medical images including radiological scans (X-ray, CT, MRI) and colonoscopy, and has performed over 4.9 million analyses to date.4
In addition to clinical products, LPIXEL also accelerates R&D across the life sciences by delivering bespoke image analysis solutions to leading pharmaceutical and medical device companies with a focus on addressing challenges across all stages of the drug development pipeline, from drug discovery to clinical trials.
For more information, please visit

About Abdul Latif Jameel General Trading Co. Ltd.
(headquartered in Chiyoda-ku, Tokyo, President and Representative Director: Shigeki ENAMI)
Established in 1996 as HOBI Co. Ltd., an affiliated office of Abdul Latif Jameel Company Ltd, the business focused on exports of vehicles manufactured by the Toyota Group to the Middle East. Today, as Abdul Latif Jameel General Trading Co. Ltd., we introduce Japanese companies and their products and services worldwide, while maintaining our core businesses centered on the Middle East and Asia. Learn more: or contact us here:


Cutting-Edge Technologies that Lead Future Medical Diagnosis
EIRL analyzes a wide range of medical data to provide an accurate and efficient diagnosis. EIRL aims to be the closest partner to all doctors, and serve as another powerful set of eyes to provide top quality medical care.
AI Accelerating
Phase R&D
IMACEL, an image analysis AI, helps to solve various issues in the drug discovery process.
Life science and AI experts support successful AI implementation.



Alphabetical listing


A Third Career Option for Researchers